INDIA SIGNS VACCINE DEVELOPMENT TREATY WITH IVI,
SOUTH KOREA
The Indian Council of Medical Research under the Department of
Health Research and the Department of Health and Family Welfare
of the Ministry of Health and Family Welfare have signed a tripartite
Memorandum of Understanding with the International Vaccine
Institute (IVI), South Korea to collaborate on vaccine research and
development.
With a long history of scientific collaboration with IVI, India officially
became a signatory to the treaty of the Seoul-based international
organization in 2012. IVI has 35 signatory countries. With this
partnership, India is committing an annual contribution of US
$5,00,000 to IVI and joins Sweden and South Korea as financially
contributing signatories to IVI.
Dr Soumya Swaminathan, Director General of ICMR, said, “We have
been working closely with IVI in India for more than a decade now.
We are confident that this collaboration will elevate the vaccine R&D
capacity at IVI as well as Indian labs and further benefit India’s vaccine
industry.”
of multinationals whose vaccines
are currently priced at more than
Rs 3000 per dose for a 3 dose
schedule.”
Playing the big role globally
In an example of India’s show
of strength aboard, recently the
Pune-based Serum Institute of
India acquired Czech biopharma
company Nanotherapeutics in a
whoppping €72 million deal that
increase its injectable Polio capacity
by 4 times. That would be a total of
200 million doses by 2019, making
it the largest injectable non oral
Polio vaccine manufacturer in the
BIOVOICENEWS.COM
15